poisar

Stocks · News reference

Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy

Vandana Singh

Arcturus partners with Thermo Fisher to support Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ARCTTMO
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Researchandmarkets.Com

    mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and More

    The global mRNA therapeutics market (excluding COVID-19 applications) is projected to grow from USD 201 million in 2026 to USD 9.98 billion by 2035, with a 63% CAGR. Growth is driven by expanding oncology and rare disease pipelines, advances in lipid nanoparticle delivery, and strategic partnerships. However, challenges include tissue-selective delivery limitations, repeat-dose tolerability concerns, and regulatory complexities. Moderna and BioNTech dominate with approximately 70% of pipeline activity.

    MRNABNTXARCT
  5. Researchandmarkets.Com

    Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share

    The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.

    TMOBIOBIO.BQGENTECH